Boston Scientific Announces Acquisition of EMcision, Limited

Acquisition expands endoscopic portfolio to include radiofrequency devices

MARLBOROUGH, Mass., March 5, 2018 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced that it has acquired EMcision, Limited, a privately held company located in the United Kingdom and Canada. The acquisition will expand the Boston Scientific Endoscopy portfolio to include the Habib™ EndoHPB probe, a novel endoscopic bipolar radiofrequency device, which coagulates tissue in the gastrointestinal (GI) tract. The Habib EndoHPB probe is used by physicians in the treatment and palliative care of patients living with pancreaticobiliary cancers.

Patients with pancreaticobiliary cancers often develop jaundice as a result of tissue ingrowth that blocks ducts that enable bile to drain out of the GI tract. The Habib EndoHPB probe coagulates this tissue to help ensure that the fluids are able to drain, which can result in an improvement in a patient's quality of life. In addition to coagulating tissue, physicians will frequently place stents to ensure that the GI tract remains open during palliative care.

"As we continue to search for ways to treat pancreaticobiliary cancers, we also seek to improve the quality of life for patients living with a cancer diagnosis today," said Art Butcher, senior vice president and president, Endoscopy, Boston Scientific. "We are committed to exploring innovative options to help increase the chance of early diagnosis, improve treatment and advance the ability to remove cancers located in challenging areas of the gastrointestinal tract."

Pancreaticobiliary cancers account for nearly a million deaths annually worldwide and have limited treatment options. While an early diagnosis improves the likelihood that a patient can meet the criteria for surgical removal of a tumor, currently only 40 percent of patients with cholangiocarcinoma and 20 percent of patients with pancreatic cancer are candidates for surgery. The EMcision products have helped thousands of patients worldwide with these difficult to treat cancers for whom surgery is not an option.

The Habib EndoHPB probe is cleared by the U.S. Food and Drug Administration and received CE mark in the European Union.

The Boston Scientific Endoscopy business offers a range of devices and solutions that help with the diagnosis, treatment and management of GI and pulmonary diseases. In November 2016, Boston Scientific acquired EndoChoice Holdings, Inc., adding pathology services, infection prevention and a range of single-use devices to its portfolio. In addition, the company is developing a range of devices to expand the field of minimally invasive endoluminal procedures as alternatives to conventional surgery for the removal of precancerous lesions and malignant tumors in the GI tract.

The acquisition of EMcision, Limited is expected to be immaterial to earnings per share (EPS) in 2018 on an adjusted and GAAP basis and accretive thereafter. Specific terms of the transaction were not disclosed.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life
by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.


Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, regulatory approvals, product development and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACTS:
Catherine Brady
Boston Scientific Corporation
508-683-4797 (office)
Catherine.brady@bsci.com

Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
(508) 683-5565 (office)